|
Celgene is poised to break-out to the upside |
|
| Oct 09, 2009 08:00 PM UTC |
|
Tracked Blogger
|
Via BloggingStocks:
Filed under: Stocks to Buy  Celgene (NASDAQ: CELG), is performing as expected, hence I'm Reiterating my Buy rating for company, first recommended on June 19, 2009 at a price of $46.94. If you bought CELG in June, you're up about 20%.Look for a 15-20% FY2009 revenue increase in CELG, boosted by cancer treatments Revlimid's and Vidaza's sales. Further, pipeline candidates to treat psoriasis and small cell lung cancer are approaching late-stage study. Continue reading Celgene is poised to break-out to the upside Celgene is poised to break-out to the upside originally appeared on BloggingStocks on Fri, 09 Oct 2009 15:00:00 EST. Please see our terms for use of feeds. Permalink | Email this | Comments
Read the rest of original post »
|
Add Comment
Be the first to comment on this story and earn 2 points.
Your Comment
|
|
IN THE PRESS |
|
|
|
|
|
|
| About | RSS | Feedback | Contact Us | Terms of Service | Privacy |
© 2009 FinancialContent Services, Inc. |
|
Data powered by FinancialContent. All Rights Reserved. Quotes delayed at least 20 minutes unless otherwise indicated. |
|
None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. |
